Updates matching "Access to Biomarker Testing"

Last week, legislation that seeks to improve New Jerseyans’ access to biomarker testing was introduced in the Legislature. Biomarker testing helps connect cancer patients to the right treatment at the right time, often resulting in improved outcomes and quality of life. In some cases, biomarker testing may provide information that enables patients to forgo ineffective treatments and eliminate the potentially harmful, life-altering side effects of those treatments, which could also result in reduced health care costs.

DENVER, COLO. — MARCH 13, 2024 — American Cancer Society Cancer Action Network (ACS CAN) volunteers from across Colorado convened at the State Capitol on Wednesday. They urged lawmakers to pass SB 124, which if enacted would ensure  biomarker testing is covered by more insurance plans, including Health First Colorado, when supported by medical and scientific evidence.

The American Cancer Society Cancer Action Network is Encouraged as Flawed Biomarker Legislation Does Not Pass

TALLAHASSEE, Fla. – March 6, 2024 – The Florida legislature passed a bill late Tuesday that expands patient access to biomarker testing, a key tool used by physicians to identify the most effective treatment of cancer and other diseases.

Cancer Advocates Urge Elected Officials to Ensure Connecticuters Have Better Access to Personalized Care

Cancer Advocates Urge the Governor to Quickly Sign This Legislation Ensuring Hoosiers Have Better Access to Personalized Care.

Cancer Advocates Urge the Senate to Do Better Than the House to Ensure West Virginians Have Better Access to Personalized Care.

SANTA FE, NEW MEX. – February 22, 2024 – State Representative Joy Garratt was honored with the ‘Legislative Champion Award’ by the American Cancer Society Cancer Action Network (ACS CAN) during a luncheon, Thursday. This award is the highest honor given by the organization. Garratt was recognized for her leading role in expanding access to biomarker testing in New Mexico. She served as a lead sponsor for HB 73 during the 2023 legislative session.

A new paper released today in the Journal of Clinical Oncology finds that while incorporating pharmacogenomic (PGx) testing into cancer care can help improve patient outcomes, barriers to PGx testing, discovery, and implementation are impacting its adoption and creating disparities that impact diverse populations.